ABC | Volume 113, Nº3, September 2019

Original Article Dracoulakis et al. High platelet activity during ASA use in ACS Arq Bras Cardiol. 2019; 113(3):357-363 1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-426. 2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.2015 ESCGuidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. 3. Nicolau JC, Timerman A, Marin-Neto JA, Piegas LS, Barbosa CJ, Franci A, et al.Guidelines of Sociedade Brasileira de Cardiologia for Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction (II Edition, 2007) 2013-2014 Update. Arq Bras Cardiol. 2014;102(3 Suppl 1):1-61. 4. Lewis HD Jr, Davis JW, ArchibaldDG, SteinkeWE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acutemyocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7):396-403. 5. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319(17):1105-11. 6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349-60. 7. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. 8. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. AmHeart J. 2007;153(2):175-81. 9. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. 10. ChenWH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007;120(7):631-5. 11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650-5. 12. Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. Thromb Haemost. 2016;116(4):638-50. 13. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25):3156-64. 14. Gori AM, Grifoni E, Valenti R, Giusti B, Paniccia R, Parodi G, et al. High on- aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. Eur J Intern Med. 2016 May;30:49-54. 15. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, ErturkM, NurkalemZ, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med. 2005;207(1):59-64. 16. Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478-93. 17. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010;103(1):71-82. 18. BuyukasikY,KarakusS,GokerH,HaznedarogluIC,OzatliD,SayinalpN,etal. RationaluseofthePFA-100device forscreeningofplateletfunctiondisorders and vonWillebrand disease. BloodCoagul Fibrinolysis. 2002;13(4):349-53. 19. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702-8. 20. Ivandic BT, Giannitsis E, Schlick P, Staritz P, Katus HA, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem. 2007;53(4):614-9. 21. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol. 2007;23(3):201-6. 22. Neubauer H, Kaiser AF, Endres HG, Krüger JC, Engelhardt A, Lask S, et al. Tailoredantiplatelettherapycanovercomeclopidogrelandaspirinresistance – the Bochum clopidogrel and aspirin plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan;9:3. 23. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17(4):433-8. 24. Gola ń ski J, Chłopicki S, Gola ń ski R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on themonitoring of aspirin antiplatelet therapy. Ther Drug Monit. 2005;27(4):484-90. 25. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10(7):1220-30. 26. Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Silberman SM, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. AmHeart J . 2012;164(4):600-6.e1. References Ethics approval and consent to participate This study was approved by the Ethics Committee of the CAPPESQ - HCFMUSP under the protocol number 0992/08. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 362